Tags

Type your tag names separated by a space and hit enter

The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients.
J Clin Endocrinol Metab. 1985 Jun; 60(6):1161-5.JC

Abstract

The acute effect of the somatostatin analog SMS 201-995 (SMS) was investigated in eight acromegalic patients. This substance is an octapeptide [DPhe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-(ol)] that inhibits GH release in experimental animals and man. After a control day, 50 micrograms SMS were injected sc, and plasma GH and insulin and blood glucose levels were measured at multiple intervals for 24 h. GH significantly (P less than 0.001) decreased in seven of eight acromegalic patients from 30 +/- 5 (+/- SE) to an average of 10.7 +/- 4 micrograms/l from 1-10 h after drug administration. No rebound effect occurred. Postprandial blood glucose levels were significantly (P less than 0.01) higher between 2 and 4 h after SMS treatment compared with control day values, and there was a substantial reduction in insulin secretion, as estimated by the area under the curve (P less than 0.01), during the first 3 h after SMS administration. Circulating GH was not altered by SMS or the dopamine agonist mesulergine in one patient, but the combination of both substances (50 micrograms SMS, sc, and 0.5 mg mesulergine, orally) reduced GH to below 50% of basal. In vitro studies showed that 1 PM, 0.1 nM, and 10 nM SMS or natural somatostatin exerted a similar inhibitory effect (12-39% reduction; P less than 0.01 for all three strengths) on GH release by cultured human pituitary tumor cells. In conclusion, the somatostatin derivative SMS exerts a potent and prolonged inhibitory action on GH secretion and a shorter lasting suppression of insulin in acromegalic patients. Therefore, it may represent a useful tool in the chronic management of this condition.

Authors

Lamberts SW
No affiliation info available
Oosterom R
No affiliation info available
Neufeld M
No affiliation info available
del Pozo E
No affiliation info available

MeSH

AcromegalyAdultAgedBlood GlucoseDose-Response Relationship, DrugFemaleGrowth HormoneHumansInsulinMaleMiddle AgedOctreotideSomatostatin

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

2860119

Citation

Lamberts, S W., et al. "The Somatostatin Analog SMS 201-995 Induces Long-acting Inhibition of Growth Hormone Secretion Without Rebound Hypersecretion in Acromegalic Patients." The Journal of Clinical Endocrinology and Metabolism, vol. 60, no. 6, 1985, pp. 1161-5.
Lamberts SW, Oosterom R, Neufeld M, et al. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab. 1985;60(6):1161-5.
Lamberts, S. W., Oosterom, R., Neufeld, M., & del Pozo, E. (1985). The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. The Journal of Clinical Endocrinology and Metabolism, 60(6), 1161-5.
Lamberts SW, et al. The Somatostatin Analog SMS 201-995 Induces Long-acting Inhibition of Growth Hormone Secretion Without Rebound Hypersecretion in Acromegalic Patients. J Clin Endocrinol Metab. 1985;60(6):1161-5. PubMed PMID: 2860119.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. AU - Lamberts,S W, AU - Oosterom,R, AU - Neufeld,M, AU - del Pozo,E, PY - 1985/6/1/pubmed PY - 1985/6/1/medline PY - 1985/6/1/entrez SP - 1161 EP - 5 JF - The Journal of clinical endocrinology and metabolism JO - J Clin Endocrinol Metab VL - 60 IS - 6 N2 - The acute effect of the somatostatin analog SMS 201-995 (SMS) was investigated in eight acromegalic patients. This substance is an octapeptide [DPhe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-(ol)] that inhibits GH release in experimental animals and man. After a control day, 50 micrograms SMS were injected sc, and plasma GH and insulin and blood glucose levels were measured at multiple intervals for 24 h. GH significantly (P less than 0.001) decreased in seven of eight acromegalic patients from 30 +/- 5 (+/- SE) to an average of 10.7 +/- 4 micrograms/l from 1-10 h after drug administration. No rebound effect occurred. Postprandial blood glucose levels were significantly (P less than 0.01) higher between 2 and 4 h after SMS treatment compared with control day values, and there was a substantial reduction in insulin secretion, as estimated by the area under the curve (P less than 0.01), during the first 3 h after SMS administration. Circulating GH was not altered by SMS or the dopamine agonist mesulergine in one patient, but the combination of both substances (50 micrograms SMS, sc, and 0.5 mg mesulergine, orally) reduced GH to below 50% of basal. In vitro studies showed that 1 PM, 0.1 nM, and 10 nM SMS or natural somatostatin exerted a similar inhibitory effect (12-39% reduction; P less than 0.01 for all three strengths) on GH release by cultured human pituitary tumor cells. In conclusion, the somatostatin derivative SMS exerts a potent and prolonged inhibitory action on GH secretion and a shorter lasting suppression of insulin in acromegalic patients. Therefore, it may represent a useful tool in the chronic management of this condition. SN - 0021-972X UR - https://www.unboundmedicine.com/medline/citation/2860119/The_somatostatin_analog_SMS_201_995_induces_long_acting_inhibition_of_growth_hormone_secretion_without_rebound_hypersecretion_in_acromegalic_patients_ DB - PRIME DP - Unbound Medicine ER -